explain the market cap, page-26

From the blog I had linked to
"Further and even more interestingly the drug makers that create the VEGF-A inhibitors are running out of their patent protection (see below). The other main drug used to treat wAMD and DME is Avastin (Bevacizumab, by Roche) which is used off-label. But these drugs have an efficacy and durability issue that seems to be lessened in combination with OPT-302.

	MOLECULE	BRAND NAME	INDICATION	MAKER	PATENT EXPIRY
1	AFLIBERCEPT	Eylea	DME	Regeneron/Bayer	2020
2	RANIBIZUMAB	Lucentis	wAMD	Genentech/Novartis	2020

(Source: here)"

Even though it will be a combo therapy, pharma companies want that patented stream of money. As the patents are ending on Eylea and Lucentis. If they get the combo patent that is a licence to print money for 10-12ish years.